Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias

被引:34
|
作者
Muayqil, Taim [1 ]
Camicioli, Richard [2 ]
机构
[1] King Saud Univ, Div Neurol, Riyadh, Saudi Arabia
[2] Univ Alberta, Div Neurol, Edmonton, AB, Canada
来源
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA | 2012年 / 2卷 / 01期
关键词
Dementia; Alzheimer; Dementia therapy; Combination treatment; Cholinesterase inhibitors; Memantine; Side effects;
D O I
10.1159/000343479
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: N-methyl-D-aspartic acid antagonists (memantine) and cholinesterase inhibitors (ChEIs) are the only two approved classes of drugs to treat dementia; this paper explores the evidence for using these two treatments in combination. Objective: To determine the efficacy and safety of using combination therapy with memantine and a ChEI to treat dementia in comparison to monotherapy with either memantine or a ChEI. Methods: In March 2012, we systematically searched MEDLINE/PubMed, EMBASE, Cochrane library, and grey literature databases. All study types were included, except for case series or reports, which looked at combination therapy versus monotherapy in various dementing disorders. Data was pooled for blinded ran-domized controlled trials (RCTs) only; mean differences and standardized mean differences were used to determine effect sizes. Results: Thirteen studies were included in this review; 3 were blinded RCTs, with a total of 971 Alzheimer's disease (AD) patients, which were included into the meta-analysis. No papers were found that primarily addressed combination therapy in other dementias. In the meta-analysis, small but statistically significant effect sizes were seen in favor of combination therapy among patients with moderate to severe AD on the scales of cognition (0.45-0.52; p < 0.0001), scales of functional outcomes (0.23-0.3; p < 0.01), and the neuropsychiatric inventory (3.7-4.4; p < 0.0001). Among the open-label studies, 3 out of 6 suggested benefits, as did the 4 included cohort studies. However, the high risk of bias encountered in the latter two study designs limits deducing any conclusions about benefit. Conclusion: Although there were statistically significant changes in favor of combination therapy in moderate to severe AD, heterogeneity in scales and patient characteristics exists. However, it is unclear if clinically significant outcomes can be achieved using the combination therapy. More studies are required before a recommendation for combination therapy can be made. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:546 / 572
页数:27
相关论文
共 50 条
  • [31] Is Periodontal Disease Associated with Alzheimer's Disease? A Systematic Review with Meta-Analysis
    Leira, Yago
    Dominguez, Clara
    Seoane, Juan
    Seoane-Romero, Juan
    Manuel Pias-Peleteiro, Juan
    Takkouche, Bahi
    Blanco, Juan
    Manuel Aldrey, Jose
    NEUROEPIDEMIOLOGY, 2017, 48 (1-2) : 21 - 31
  • [32] Repetitive Behaviors in Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Polin, Clement
    Gelle, Thibaut
    Auditeau, Emilie
    Adou, Caroline
    Clement, Jean-Pierre
    Calvet, Benjamin
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 96 (02) : 483 - 497
  • [33] Dopamine and Dopamine Receptors in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis
    Pan, Xiongfeng
    Kaminga, Atipafsa C.
    Wen, Shi Wu
    Wu, Xinyin
    Acheampong, Kwabena
    Liu, Aizhong
    FRONTIERS IN AGING NEUROSCIENCE, 2019, 11
  • [34] The value of cholinesterase inhibitors for improving neuropsychiatric and functional assessment scores in patients with Alzheimer disease: a systematic review and meta-analysis of on placebo-controlled RCTs
    Zhang, Yamin
    Sun, Yanqing
    Hu, Xiaojuan
    Yao, Yuping
    Wang, Jianping
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (06) : 3937 - 3945
  • [35] Efficacy and safety of transcranial magnetic stimulation on cognition in mild cognitive impairment, Alzheimer's disease, Alzheimer's disease-related dementias, and other cognitive disorders: a systematic review and meta-analysis
    Pagali, Sandeep R.
    Kumar, Rakesh
    LeMahieu, Allison M.
    Basso, Michael R.
    Boeve, Bradley F.
    Croarkin, Paul E.
    Geske, Jennifer R.
    Hassett, Leslie C.
    Huston, John
    Kung, Simon
    Lundstrom, Brian N.
    Petersen, Ronald C.
    St. Louis, Erik K.
    Welker, Kirk M.
    Worrell, Gregory A.
    Pascual-Leone, Alvaro
    Lapid, Maria I.
    INTERNATIONAL PSYCHOGERIATRICS, 2024, 36 (10) : 880 - 928
  • [36] Diet and biomarkers of Alzheimer's disease: a systematic review and meta-analysis
    Hill, Edward
    Goodwill, Alicia M.
    Gorelik, Alexandra
    Szoeke, Cassandra
    NEUROBIOLOGY OF AGING, 2019, 76 : 45 - 52
  • [37] Memantine for Lewy Body Disorders: Systematic Review and Meta-Analysis
    Matsunaga, Shinji
    Kishi, Taro
    Iwata, Nakao
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2015, 23 (04) : 373 - 383
  • [38] EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease
    Schmidt, R.
    Hofer, E.
    Bouwman, F. H.
    Buerger, K.
    Cordonnier, C.
    Fladby, T.
    Galimberti, D.
    Georges, J.
    Heneka, M. T.
    Hort, J.
    Laczo, J.
    Molinuevo, J. L.
    O'Brien, J. T.
    Religa, D.
    Scheltens, P.
    Schott, J. M.
    Sorbi, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (06) : 889 - 898
  • [39] The controversial promises of cholinesterase inhibitors for Alzheimer's disease and related dementias: A qualitative study of caregivers' experiences
    Smith, Andre
    Kobayashi, Karen
    Chappell, Neena
    Hoxsey, Dann
    JOURNAL OF AGING STUDIES, 2011, 25 (04) : 397 - 406
  • [40] Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
    Julio Zarra
    Luisa Schmidt
    Annals of General Psychiatry, 9 (Suppl 1)